Answers are grounded in this paper and cite their sources.
Dear Editor,We read with interest the structured benefit–risk assessment by Blauvelt et al. which concluded that dupilumab had a higher 24-week overall score than upadacitinib (66 vs 61) and sugges...
No takes yet. Share an insight, caveat, or question.
Yılmaz et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: